NEW YORK (GenomeWeb News) – New Delhi-based Super Religare Laboratories will distribute Rosetta Genomics’ three microRNA-based cancer tests in India, Saudi Arabia, Qatar, and United Arab Emirates, Rosetta said today.
SRL will send the samples from the four countries to Rosetta Genomics’ CLIA-certified lab in Philadelphia for analysis.
“Our unique technology, mainly the use of microRNAs as biomarkers, and their stability in formalin fixed paraffin embedded blocks, will enable us to easily receive samples from around the world, without the need for temperature-controlled shipments,” Ronen Tamir, Rosetta Genomics’ chief commercialization officer, said in a statement.
The agreement covers Rosetta Genomics’ miRview test line, including the miRview mets test to identify the primary tumor site in patients with cancer of unknown primary origin, the miRview squamous test for differentiating squamous from non-squamous small cell lung cancer, and the miRview meso test for differentiating mesothelioma from other carcinomas in the lung.
“The two companies have also discussed the possibility to expand their relationship into research and development projects,” SRL’s CEO, Sanjeev Chaudhry, said in a statement.